Evidence map›Paper›PMID 37200322›Full record

ArticlePloS one2023

Community-based COVID-19 active case finding and rapid response in the Democratic Republic of the Congo: Improving case detection and response.

John Otokoye Otshudiema, Gervais Léon Tengomo Folefack, Justus M Nsio, Cathy H Kakema, Luigino Minikulu, Aimé Bafuana, Joel B Kosianza, Antoine K Mfumu, Edith Nkwembe, Yannick Munyeku-Bazitama and 18 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 4 institutions in 3 countries.

John Otokoye OtshudiemaCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.ORCID 0000-0001-9946-7951
Gervais Léon Tengomo FolefackCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
Justus M NsioCOVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo.
Cathy H KakemaCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
Luigino MinikuluCOVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo.
Aimé BafuanaCOVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo.
Joel B KosianzaCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
Antoine K MfumuCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.ORCID 0000-0003-0702-1261
Edith NkwembeCOVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.
Yannick Munyeku-BazitamaCOVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.ORCID 0000-0001-8303-318X
Sheila Makiala-MandandaCOVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.
Noé GuinkoCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
Gisèle MbuyiCOVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo.ORCID 0000-0001-6261-8277
Jean-Marie K TshilumbuCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
Guy N SaidiCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
Moreau-Serge Umba-di-MasialaCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
Amos K EbondoCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
Jean-Jacques MutonjCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
Serge KalomboCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
Jad KabeyaCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
Taty K MawandaCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
Faustin N BileCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
Gaby K KaserekaCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
Placide Mbala-KingebeniCOVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.
Steve Ahuka-MundekeCOVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.
Humphrey Cyprian KaramagiData Analytics and Knowledge Management, World Health Organization Regional Office for Africa, Brazzaville, Democratic Republic of Congo.ORCID 0000-0002-6277-2095
Karl Njuwa FaiResearch Arm - MSF Epicentre, Yaoundé, Cameroon.ORCID 0000-0001-5395-0091
Amédée Prosper DjiguimdeCOVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
National Institute of Biomedical Research · CDMinistry of Public Health · CDUnited Nations Children's Fund Cameroon · CMWorld Health Organization Regional Office for Africa · CG

Funding

World Health Organization 001
6 · The paper itself

Abstract

A community-based coronavirus disease (COVID-19) active case-finding strategy using an antigen-detecting rapid diagnostic test (Ag-RDT) was implemented in the Democratic Republic of Congo (DRC) to enhance COVID-19 case detection. With this pilot community-based active case finding and response program that was designed as a clinical, prospective testing performance, and implementation study, we aimed to identify insights to improve community diagnosis and rapid response to COVID-19. This pilot study was modeled on the DRC's National COVID-19 Response Plan and the COVID-19 Ag-RDT screening algorithm defined by the World Health Organization (WHO), with case findings implemented in 259 health areas, 39 health zones, and 9 provinces. In each health area, a 7-member interdisciplinary field team tested the close contacts (ring strategy) and applied preventive and control measures to each confirmed case. The COVID-19 testing capacity increased from 0.3 tests per 10,000 inhabitants per week in the first wave to 0.4, 1.6, and 2.2 in the second, third, and fourth waves, respectively. From January to November 2021, this capacity increase contributed to an average of 10.5% of COVID-19 tests in the DRC, with 7,110 positive Ag-RDT results for 40,226 suspected cases and close contacts who were tested (53.6% female, median age: 37 years [interquartile range: 26.0-50.0)]. Overall, 79.7% (n = 32,071) of the participants were symptomatic and 7.6% (n = 3,073) had comorbidities. The Ag-RDT sensitivity and specificity were 55.5% and 99.0%, respectively, based on reverse transcription polymerase chain reaction analysis, and there was substantial agreement between the tests (k = 0.63). Despite its limited sensitivity, the Ag-RDT has improved COVID-19 testing capacity, enabling earlier detection, isolation, and treatment of COVID-19 cases. Our findings support the community testing of suspected cases and asymptomatic close contacts of confirmed cases to reduce disease spread and virus transmission.

Indexed as

COVID-19AdultCOVID-19 TestingDemocratic Republic of the CongoFemaleHumansMalePilot ProjectsProspective StudiesSensitivity and Specificity

Identifiers

PMID37200322
PMCPMC10194859
OpenAlexW4377047580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.